دانلود رایگان مقاله فایده توموگرافی گسیل پوزیترون برای توسعه دارو برای نارسایی قلبی

Only about 1 in 5,000 investigational agents in a preclinical stage acquires Food and Drug Administration approval. Among many reasons for this includes an inefficient transition from preclinical to clinical phases, which exponentially increase the cost and the delays the process of drug development. Positron emission tomography (PET) is a nuclear imaging technique that has been used for the diagnosis, risk stratification, and guidance of therapy. However, lately with the advance of radiochemistry and of molecular imaging technology, it became evident that PET could help novel drug development process. By using a PET radioligand to report on receptor occupancy during novel agent therapy, it may help assess the effectiveness, efficacy, and safety of such a new medication in an early preclinical stage and help design successful clinical trials even at a later phase. In this article, we explore the potential implications of PET in the development of new heart failure therapies and review PET's application in the respective pathophysiologic pathways such as myocardial perfusion, metabolism, innervation, inflammation, apoptosis, and cardiac remodeling. (Am Heart J 2016;175:142-52.)

Conclusion

Positron emission tomography is a mature imaging technique, with continuously growing acceptance worldwide. Beyond its applicability in diagnosis, stratification, and understanding of pathophysiology in oncology and neurology/psychiatry, the growth of radiochemistry and of novel combined molecular imaging technologies opens new horizons in cardiology and in HF, in particular. The evolution of PET could help either in the early-phase drug trials, by confirming the successful drug–tissue target interaction, or in phase II/III trials with the more convenient determination of effectiveness, efficacy, and safety and the preselection of more appropriate candidates for these emerging treatments. This might boost the transition of new under investigation agents to later-phase trials and production, by reducing the temporal and financial burden, thus providing earlier access to more promising therapies for millions of patients worldwide.